BrainHeal(th) on Nostr: https://www.youtube.com/watch?v=WngW-uvO18A In the last several videos, we’ve been ...
https://www.youtube.com/watch?v=WngW-uvO18A
In the last several videos, we’ve been talking about Dr. Bredesen’s first book, published in 2017, that had served as the first playbook for my dad: The End of Alzheimer’s: The First Program to Prevent and Reverse Cognitive Decline. We’ve specifically been talking about the ReCODE Protocol, which he details in the book.
ReCODE for Reversal of Cognitive Decline, which is a personalized protocol that addresses multiple factors contributing to someone’s cognitive issues, bringing them back to optimal ranges and helping patients reverse disease and symptoms. Dr. Bredesen’s team has helped hundreds of people reverse their cognitive decline, established mild cognitive impairment and Alzheimer’s Disease with this protocol, as evidenced in successful studies in 2014, 2018, 2022 and current clinical trials.
In this video, we’re going to transition from the testing phase of ReCODE to the treatment phase.
As a quick recap:
Because ReCODE is a personalized program that’s tailored to how every patient tests on individualized evaluations, this first phase screens for all the risk factors that contribute to cognitive health and decline. Dr. Bredesen calls this phase the Cognoscopy.
All of these tests and lab results paint a clear picture of where a patient stands and how they got there. These results are then used to identify which sub-type of Alzheimer’s, or preceding cognitive decline states, we’re predominantly dealing with.
Dr. Bredesen’s subtypes, again are:
Type 1: Inflammatory
Type 2: Atrophic
Type 3: Toxic
And then there was a bonus subtype that Dr. Bredesen found to be a combination of type 1 and 2:
Type 1.5: Glycotoxic
Once the Cognoscopy is complete and a subtype has been established, a personalized protocol can be built out for the patient.
Watch Episodes 10-14 for more details on this phase, especially for how to find the best medical practitioner to help you manage the protocol and which key lab tests to prioritize.
Dr. Bredesen found that patients that were already experiencing pronounced cognitive decline had on average between 10-25 blood lab values that were abnormal to suboptimal. And in patients that had just a few recognizable symptoms, maybe were working on prevention, and had strong family history, they had on average 3-5 lab values out of range.
The important point is that Dr. Bredesen’s team has demonstrated that each of these values can be returned to healthy and even optimal. The ReCODE Protocol calls for addressing all of these, and every patient’s program may be slightly different and personalized to them, but here are the 9 foundational principles Dr. Bredesen wants everyone’s treatment plan to follow...
Hope this is helpful for you and your family. Thank you for watching!
#alzheimers
#earlyonsetalzheimers
#alzheimersprevention
#alzheimersreversal
#mildcognitiveimpairment
#dementia
#bredesenprotocol
#recodeprotocol
#apoe4
#brainhealth
#brainhealing
In the last several videos, we’ve been talking about Dr. Bredesen’s first book, published in 2017, that had served as the first playbook for my dad: The End of Alzheimer’s: The First Program to Prevent and Reverse Cognitive Decline. We’ve specifically been talking about the ReCODE Protocol, which he details in the book.
ReCODE for Reversal of Cognitive Decline, which is a personalized protocol that addresses multiple factors contributing to someone’s cognitive issues, bringing them back to optimal ranges and helping patients reverse disease and symptoms. Dr. Bredesen’s team has helped hundreds of people reverse their cognitive decline, established mild cognitive impairment and Alzheimer’s Disease with this protocol, as evidenced in successful studies in 2014, 2018, 2022 and current clinical trials.
In this video, we’re going to transition from the testing phase of ReCODE to the treatment phase.
As a quick recap:
Because ReCODE is a personalized program that’s tailored to how every patient tests on individualized evaluations, this first phase screens for all the risk factors that contribute to cognitive health and decline. Dr. Bredesen calls this phase the Cognoscopy.
All of these tests and lab results paint a clear picture of where a patient stands and how they got there. These results are then used to identify which sub-type of Alzheimer’s, or preceding cognitive decline states, we’re predominantly dealing with.
Dr. Bredesen’s subtypes, again are:
Type 1: Inflammatory
Type 2: Atrophic
Type 3: Toxic
And then there was a bonus subtype that Dr. Bredesen found to be a combination of type 1 and 2:
Type 1.5: Glycotoxic
Once the Cognoscopy is complete and a subtype has been established, a personalized protocol can be built out for the patient.
Watch Episodes 10-14 for more details on this phase, especially for how to find the best medical practitioner to help you manage the protocol and which key lab tests to prioritize.
Dr. Bredesen found that patients that were already experiencing pronounced cognitive decline had on average between 10-25 blood lab values that were abnormal to suboptimal. And in patients that had just a few recognizable symptoms, maybe were working on prevention, and had strong family history, they had on average 3-5 lab values out of range.
The important point is that Dr. Bredesen’s team has demonstrated that each of these values can be returned to healthy and even optimal. The ReCODE Protocol calls for addressing all of these, and every patient’s program may be slightly different and personalized to them, but here are the 9 foundational principles Dr. Bredesen wants everyone’s treatment plan to follow...
Hope this is helpful for you and your family. Thank you for watching!
#alzheimers
#earlyonsetalzheimers
#alzheimersprevention
#alzheimersreversal
#mildcognitiveimpairment
#dementia
#bredesenprotocol
#recodeprotocol
#apoe4
#brainhealth
#brainhealing